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Abstract
Purpose of review The study aims to describe the evidence-
based management and controversies in blunt splenic trauma.
Recent findings A shift from operative management to non-
operative management (NOM) has occurred over the past de-
cades where NOM has now become the standard of care in
haemodynamically stable patients with blunt splenic injury.
Splenic artery embolisation (SAE) is generally believed to
increase the success rate of NOM. Not all the available evi-
dence is that optimistic about SAE however. A morbidity
specifically related to SAE of up to 47% has been reported.
Although high-grade splenic injury is a prognostic factor for
failure of NOM, an American research group has published a
study in which NOM is performed in over half of haemody-
namically stable patients with grade IV or V splenic injury
without leading to an increased morbidity (in terms of com-
plications) or mortality. Another area of current investigation
in the literature is the exact indication for SAE. Although the
generally accepted indication is the presence of vascular inju-
ry, a topic of current investigation is whether there might be a
role for pre-emptive embolisation in patients with high-grade
splenic injury. On the other hand, evidence is also emerging
that not all blushes require an intervention (small blushes <1
or 1.5 cm do not). Lastly, the available evidence shows that
splenic function is preserved after embolisation, and therefore,
the routine administration of vaccinations seems not to be
necessary. There might be a difference between proximal
and distal embolisations; however, with regard to splenic
function, in favour of distal embolisation.
Summary Nowadays, NOM is the standard of care in haemo-
dynamically stable patients with blunt splenic injury. The
available evidence (although with a relatively small number
of patients) shows that splenic function is preserved after
NOM, a major advantage compared to splenectomy. SAE is
used as an adjunct to observation in order to increase the
success rate of NOM. Operative management should be ap-
plied in case of haemodynamic instability or if associated
intra-abdominal injuries requiring surgical treatment are pres-
ent. Patient selection (which patient can be safely treated non-
operatively, does every blush needs to be embolised?, which
patients might be better off with direct operative intervention
given the patient and injury characteristics) is an ongoing sub-
ject of further research. Future studies should also focus on
long-term outcomes of patients treated with embolisation (e.g.
total number of lifetime infectious episodes requiring antibi-
otic treatment or hospital admission, quality of life).
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Introduction
Nearly 199,800 people die from injury each year—1 person
every 3 min [1]. Trauma is the most common cause of death in
people under the age of 45 years and in the top 3 leading
causes of death in all age groups [2]. The prevalence of
intra-abdominal injury amongst patients presenting to the
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emergency department is around 15%, and the spleen is the
most commonly injured organ in blunt abdominal trauma [3].
In the past decades, the treatment of patients with blunt
splenic injury has shifted from operative to non-operative
management (NOM). Operative management was applied be-
cause of the belief that the spleen was an organ without func-
tion, that it could not heal on its own and could rupture in a
later stage. Also, the mortality rate of patients who were not
operated was unacceptably high, whereas patients who were
operated had a change of survival [4]. Nowadays, splenic
artery embolisation (SAE) has become available and well
studied. This has led to NOM being the treatment of choice.
NOM has several advantages over operative management.
First of all, the risk of overwhelming post-splenectomy infec-
tion, an infection caused by encapsulated bacteria, which oc-
curs after only 0.5% of all splenectomies in trauma patients
but carries a mortality rate of around 50 to 70% [5], is avoided.
Second, in case of failure of NOM, there is the possibility of a
second non-operative re-intervention, for example an attempt
for SAE after failure of observation or proximal embolisation
after failure of distal embolisation. Third of all, possible
surgery-related complications are avoided. Lastly, a shorter
hospitalisation period and a concomitant reduction in costs
have been reported in the literature [6]. However, disadvan-
tages of NOM exist as well. There is a risk of delayed splenic
rupture, the possibility of re-bleeding and minor or major
complications of embolisation might occur (e.g. splenic in-
farction, splenic abscess, contrast-induced renal insufficiency,
coil migration or pleural effusion [7, 8]), and the fact that no
(intra-operative) view can be obtained of other abdominal or-
gans is an important disadvantage.
In this review, evidence-based management and controver-
sies in blunt splenic trauma are discussed and future perspec-
tives are highlighted.
Non-operative Management
NOM consists of close observation of the patient and can be
supplemented with SAE if necessary. Observational manage-
ment involves admission to a medium or intensive care unit
with close monitoring of vital signs, bed rest, frequent moni-
toring of hemoglobin concentration, and serial abdominal ex-
aminations [9]. Therefore, the first important necessities in
order to safely perform NOM are facilities with continuous
monitoring of vital signs, the possibility for transfusion, and
the manpower for re-assessment of the patient (several times a
day). Also, the hospital should have unlimited access to a CT
scanner with intravenous contrast administration, preferably
on or close to the trauma room/emergency department [10•].
Furthermore, interventional radiological facilities, i.e. 24-h
coverage of an experienced interventional radiologist, and all
the required resources should be available. If a hospital is not
able to meet these requirements, NOM should not be chosen
over surgical management.
Splenic Artery Embolisation
Indications for SAE are the presence of vascular injury such as
cont ras t ex t ravasa t ion ( i .e . a b lush) , a cut -off ,
pseudoaneurysms, or arteriovenous fistula. Different types of
embolisation exist: proximal (arteria lienalis) or distal (also
called selective) embolisation.
Embolisation is generally believed to increase the success
rate (outcome: splenic salvage rate) of observation [11].
However, the true additional value of SAE has not been well
defined yet. According to Harbrecht et al. [12], improvement
in the success rate of NOM of patients with blunt splenic
injuries over time is caused, in part, by an increase in the
detection of relatively minor splenic injuries by qualitatively
better CT scanners. The results of the propensity score analy-
sis [13] suggest that the improvement in success might be
attributed to the use of SAE, although there was no significant
difference between SAE and observation alone with regard to
successful treatment after correction for confounders.
More recently, critical evidence appeared with regard to
SAE. Chastang et al. [14] questioned the indication for SAE
because of the high overall morbidity of 44% (the authors
investigated both morbidity related to splenic injury and se-
verity, morbidity related to associated trauma, and morbidity
specifically related to treatment). In their study, the morbidity
specifically related to SAE was 47% (7 out of 15 patients
treated with embolisation) and consisted of major splenic in-
farctions, probably leading to functional asplenism and post-
embolisation syndromes (hyperthermia, hyperalgia without
splenic infarction). Although the results are based on small
numbers, a description of the years of experience of the inter-
ventional radiologists is lacking, and this high number of com-
plications has not been described by other authors they are
alarming and should be put into perspective in future compar-
ative studies. Furthermore, the most important early disadvan-
tage of SAE is not the above-described complications but the
possibility of re-bleeding (i.e. failure of NOM).
Failure of NOM
The failure rate of NOM is around 10%. Early identification of
patients at high risk for failure of NOM (eventually requiring a
re-intervention, (repeat) SAE, or delayed splenectomy) is es-
sential since delay in recognition and treatment of late splenic
ruptures leads to increased resource use, morbidity, and mor-
tality (preventable deaths) [15, 16]. Many prognostic factors
for failure have been investigated in the literature, such as
grade of splenic injury, the presence of a (large)
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haemoperitoneum, contrast extravasation at time of admis-
sion, high Injury Severity Score (ISS), lower admission sys-
tolic blood pressure (SBP), transfusion of >1 packed cell, and
the presence of traumatic brain injury. In a study with almost
15,000 patients, Peitzman et al. reported that the failure rate of
NOM increased with grade of injury from 4.8% for patients
with American Association for the Surgery of Trauma (AAST,
see Table 1 in the Appendix) grade I injury, 9.5% for grade II,
19.6% for grade III, 33.3% for grade IV, and 75.0% for grade
V, respectively. Higher failure rates with increasing grade of
splenic injury were also found by Chastang et al. [14] in a
prospective, multicentre study. In a systematic review, strong
evidence was found that splenic injury grade ≥3, ISS ≥25, and
age ≥40 years affect the outcome of NOM [17]. Awareness is
needed because in the presence of these factors, NOM
is more likely to fail. Limited evidence was available
for a lowered GCS score/the presence of traumatic brain
injury.
Although NOM is more likely to fail in patients with high-
grade splenic injury, high-grade splenic injury (in haemody-
namically stable patients) is not necessarily a contraindication
for NOM. Scarborough et al. recently published data of 1516
patients (propensity-matched cohort) with high-grade splenic
injury (grades IV and V) in which NOM was compared to
immediate splenectomy. NOM was attempted in over half of
the patients (52.2%). Interestingly, in approximately 20% of
the patients with a NOM attempt, splenectomy was ultimately
required. While increasing patient age, hypotension on admis-
sion, the presence of any underlying bleeding disorder, and
grade V splenic injury (compared to grade IV) increased fail-
ure rate, the only protective factor against failure of NOMwas
the use of SAE. Delay in operative management (in other
words, failure of NOM) did not affect mortality (6.4% in fail-
ure of NOM group vs 16.4% in immediate splenectomy
group) or the number of (non)infectious complications, but
the hospital length of stay was significantly longer compared
to patients undergoing immediate splenectomy [18•].
An eventual further extension of SAE (not only in case of
the presence of vascular injury) is currently being investigated
by Gaarder et al. from Oslo. They are preparing a randomised
controlled (multicentre) trial in which failure rate (due to splen-
ic bleeding) of NOM is compared between haemodynamically
stable patients with high-grade (IVor V) splenic injury under-
going pre-emptive SAE and patients not undergoing SAE.
As important as recognising the risk of failure is being
aware of the time interval between trauma and failure.
Different research groups have investigated this topic.
Peitzman et al. [19] reported that over 85% of the failures
occurred in the first 72 h after injury (data of almost 15,000
patients). Smith et al. analysed over 23,000 patients and found
that over 95% of failures occurred within the first 3 days and
that 2 additional days of hospital admission only captured
1.5% more failures [20••]. Zarzaur et al. performed a
prospective study in which the risk of splenectomy (after a
minimum of 24-h observation and non-operative attempt)
was 0.27% in a time period of 180 days (total follow-up du-
ration) with a median hospital length of stay of 6 days (range 3
to 11). They state that for grade II to V splenic injury, close
observation (in hospital or as an outpatient with good instruc-
tions) is needed for a total of 10–14 days [21]. Awareness with
regard to time to failure is important because it influences the
duration of hospital admission. In the Delphi study (expert
consensus study), agreement was reached that optimal dura-
tion of hospital admission consists of 1–3 days of admission to
a monitored setting followed by 1–3 days of admission to a
surgical ward [22].
The value of routine follow-up imaging has been debated
in the literature. Some authors use routine follow-up CT scan-
ning (at 48 h) to decrease the failure rate of NOM [14, 23] or in
order to confirm healing [24] whilst others do only support it
routinely [22] or not at all [25]. Serial CTs may be considered
for high-level athletes on a case-by-case basis [26].
Splenic function
The spleen has both an haematological and immunological
function. With regard to its immunological function, it is in-
volved in the antibody response against infection, most im-
portantly against encapsulated bacteria such as Streptococcus
pneumoniae, Haemophilus influenzae type B, and Neisseria
meningitides group C [27, 28]. One of the biggest advantages
of NOM is preservation of splenic function. Different studies
have investigated splenic function after SAE, most of them
concluding that immunocompetence of the spleen is preserved
[29–32]. However, no gold standard exists for measuring
splenic function and the majority of the studies performed
are retrospective in nature and/or included a relatively small
number of patients. Olthof et al. performed a prospective
study in which splenic function of embolised patients was
compared to function of both healthy controls and patients
who underwent splenectomy. Splenic function was assessed
(amongst others) by the antibody response to pneumococcal
23-valent polysaccharide vaccine (the ratio of the IgG anti-
body level post vaccination compared to pre vaccination
with a ratio <2 being considered as an insufficient response).
The median vaccine-specific antibody response of the SAE
patients (fold increase 3.97) did not differ significantly from
that of the healthy controls (5.29; P = 0.90). The numbers
were too small to investigate whether a difference exists be-
tween proximal and distal embolisation, but in two of the
proximally embolised patients and none of the distally
embolised patients, the ratio of the IgG antibody level post
vaccination compared to pre vaccination was <2 [33•]. Foley
et al. compared 38 patients who underwent proximal
embolisation with 11 patients who underwent distal
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embolisation (and who were prospectively enrolled). Splenic
function was measured in terms of IgM memory B cell
numbers as a percentage of total B cells. There was no
difference between the patients with proximal and distal
embolisation (7.55 (6.11–9.31) vs. 9.97 (6.75–14.74)).
However, there was a significant difference between the
control group and the proximally embolised group (10.75
(9.58–12.06) vs. 7.55 (6.11–9.31)); p value 0.02) [34].
Currently, a multicenter trial is being conducted (by the
Davis Medical Center of the University of California) in
which a total number of 90 patients will be enrolled (30
patients treated with observation, 30 with embolisation, and
30 operatively treated patients) and compared with regard to
splenic function, measured by geometric mean increases in
pneumococcal antibody titre [35]. With the available
evidence, we could say that routine vaccination is not
indicated.
Indications for Surgery
Whereas currently over 60–95% of the patients are
treated non-operatively, accepted criteria for operative
management have long been haemodynamic instability
and associated intra-abdominal or pelvic injury requiring
operative intervention. Time to intervention (to stop the
bleeding) is another argument that is believed to be in
favour of surgery. However, in our institution, we have
compared time to embolisation with time to surgery.
Median time to intervention did not differ, even in hae-
modynamically unstable patients (the median time to
embolisation in haemodynamically stable patients was
177 min (IQR 78–233 min) vs 95 min (IQR 69–
188 min) in the surgically treated patients and 46 min
(IQR 27–107) vs. 64 min (IQR 45–80) in haemodynam-
ically unstable patients) [36]. These data show that em-
bolisation can safely be performed in haemodynamically
unstable patients (defined as SBP ≤100 mmHg and
heart rate >120 bpm on admission). It should be noted,
however, that this concerns unstable patients with iso-
lated blunt splenic injury. Also, an important requisite
for this management is the 24-h availability of an inter-
ventional radiologist team and all the necessary re-
sources. This should not be underestimated and remains
to be the restrictive factor in wider implementation
worldwide.
Different surgical techniques to control splenic bleeding
exist, the classic (and most quick) method being splenec-
tomy. Other techniques such as packing, splenorrhaphy,
partial splenectomy, or the use of local haemostatic agents,
such as Tachosyl® or Floseal®, can also be used. In gener-
al, if the lesion is small or there is only a local bleeding
site, haemostatic agents can be applied or the defect can be
surgically sutured. For AAST grade IV or V injury, sple-
nectomy is the surgical method of choice.
Current and Future Perspectives
The trend towards NOM is evolving, and further refine-
ment of patient selection is an important subject in cur-
rent scientific research: who is a safe candidate for ob-
servation, who benefits from embolisation, and who
needs (direct) surgical treatment. Although the presence
of vascular injury is an indication for embolisation, new
evidence is emerging that not all blushes require an in-
tervention. Not only the location but also the size of a
blush is important. Two research groups have published
evidence that only blushes >1 and >1.5 cm correlate with
the need for intervention [37, 38]. These findings should
be confirmed in larger studies also including more di-
verse patient groups (i.e. also patients with blood clotting
disorders or patients who take antithrombotic agents) be-
fore these criteria can be implemented in clinical
practice.
We live in a world where rapid advancements are
made, especially in technology. Nowadays, a number
of hospitals have a hybrid operating theatre in place,
where diagnostics and therapeutic (both endovascular
and open surgical) techniques can be combined (see
Fig. 1) [39]. This maximises patient’s benefit and allows
us to stop the bleeding as quickly as possible according
to one of the principles of trauma surgery: ‘Time is
life’. Brenner et al. describe an interesting future per-
spective where the skill set of the acute care surgeon or
trauma surgeon can be expanded with endovascular
techniques. This results in surgeons themselves to per-
form splenic (or other abdominal/pelvic) embolisation
[40], the big advantage being that the person performing
the endovascular technique is also very familiar with
Fig. 1 Example of a hybrid operating room in the Academic Medical
Center in Amsterdam
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polytraumatised patients, particularly when actively
bleeding.
Conclusion
The vast majority (60–90%) of the patients with splenic injury
are treated non-operatively with success rates over 80%. A
major advantage of NOM could be that splenic function is
preserved as is suggested by the currently available literature
(larger trials currently recruiting patients). However, disad-
vantages of NOM are the (small) risk of delayed splenic
rupture, the possibility of a re-bleed, and the fact that
no view is obtained of other abdominal organs.
Especially in patients with multiple organ injuries, the
latter should be considered.
Prognostic factors for failure of NOM include high-
grade splenic injury grade (AAST grade 3 or higher),
Injury Severity Score ≥25, and age ≥40 years. SAE can
be used as an adjunct to observation in order to increase
the success rate of NOM in patients with vascular injury
(contrast extravasation, arteriovenous fistula, or
pseudoaneurysm) or maybe even pre-emptively in pa-
tients with high-grade splenic injury (currently under
investigation). Operative management is still indicated
in case of haemodynamic instability (not responding to
transfusion) or when associated intra-abdominal injuries
requiring surgical treatment are present. It should be
noted that in hospitals without sophisticated interven-
tional radiological facilities (i.e. 24-h coverage of an
experienced interventional radiologist and all the re-
quired resources), NOM should not be chosen over sur-
gical management.
The challenge remains to stop the bleeding as quickly
as possible by applying the most suitable or least inva-
sive technique, reducing the number of unnecessary
splenectomies in a safe manner (without increasing
complication rate, readmission rate, or morbidity), there-
by maximising patients’ benefit. Patient selection should
be an ongoing subject of further research. Future studies
should also focus on long-term outcomes (e.g. infectious
episodes requiring antibiotic treatment or hospital ad-
mission, quality of life) of patients treated with
embolisation.
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